Related references
Note: Only part of the references are listed.Fallopian Tube Intraluminal Tumor Spread From Noninvasive Precursor Lesions
Jonathan G. Bijron et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2013)
Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program
Pal Moller et al.
BREAST CANCER RESEARCH AND TREATMENT (2013)
Ten-Year Survival in Patients With BRCA1-Negative and BRCA1-Positive Breast Cancer
Tomasz Huzarski et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Germline BRCA Mutations Are Associated With Higher Risk of Nodal Involvement, Distant Metastasis, and Poor Survival Outcomes in Prostate Cancer
Elena Castro et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Cancer Risks for BRCA1 and BRCA2 Mutation Carriers: Results From Prospective Analysis of EMBRACE
Nasim Mavaddat et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2013)
Familial prostate cancer: the damage done and lessons learnt
Nassim Taherian et al.
NATURE REVIEWS UROLOGY (2013)
Gene Patenting The Supreme Court Finally Speaks
Aaron S. Kesselheim et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
J. Iqbal et al.
BRITISH JOURNAL OF CANCER (2012)
Long-term results of screening with magnetic resonance imaging in women with BRCA mutations
K. Passaperuma et al.
BRITISH JOURNAL OF CANCER (2012)
Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer
Zsofia K. Stadler et al.
CANCER (2012)
Size surprise? Tumour size, nodal status, and outcome after breast cancer
W. D. Foulkes
CURRENT ONCOLOGY (2012)
BRCA, the Oviduct, and the Space and Time Continuum of Pelvic Serous Carcinogenesis
Christopher P. Crum et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2012)
Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Tomasz Byrski et al.
BREAST CANCER RESEARCH (2012)
Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study
Anita V. Mitra et al.
BJU INTERNATIONAL (2011)
BRCA2 is a moderate penetrance gene contributing to young-onset prostate cancer: implications for genetic testing in prostate cancer patients
Z. Kote-Jarai et al.
BRITISH JOURNAL OF CANCER (2011)
Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy
Amir Sonnenblick et al.
CANCER BIOLOGY & THERAPY (2011)
Response to Neoadjuvant Systemic Therapy for Breast Cancer in BRCA Mutation Carriers and Noncarriers: A Single-Institution Experience
Banu Arun et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Efficacy of Neoadjuvant Cisplatin in Triple-Negative Breast Cancer
Daniel P. Silver et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
BRCA1-Associated Breast Cancers Present Differently From BRCA2-Associated and Familial Cases: Long-Term Follow-Up of the Dutch MRISC Screening Study
Adriana J. Rijnsburger et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Pathologic Complete Response Rates in Young Women With BRCA1-Positive Breast Cancers After Neoadjuvant Chemotherapy
Tomasz Byrski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Family History of Cancer and Cancer Risks in Women with BRCA1 or BRCA2 Mutations
Kelly Metcalfe et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew Tutt et al.
LANCET (2010)
Tumor size and survival in breast cancer-a reappraisal
William D. Foulkes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
Prolonged survival in a patient with BRCA2 associated metastatic pancreatic cancer after exposure to camptothecin: a case report and review of literature
Edward James et al.
ANTI-CANCER DRUGS (2009)
Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients
T. Byrski et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers.
Peter C. Fong et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Rapid progression of prostate cancer in men with a BRCA2 mutation
S. A. Narod et al.
BRITISH JOURNAL OF CANCER (2008)
A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations
Ann K. Folkins et al.
GYNECOLOGIC ONCOLOGY (2008)
Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations
Gad Rennert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Prostate cancer progression and survival in BRCA2 mutation carriers
Laufey Tryggvadottir et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Meta-analysis of BRCA1 and BRCA2 penetrance
Sining Chen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The prevalence of BRCA2 mutations in familial pancreatic cancer
Fergus J. Couch et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2007)
The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome
F Medeiros et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2006)
Cancer risks in BRCA2 families:: estimates for sites other than breast and ovary
CJ van Asperen et al.
JOURNAL OF MEDICAL GENETICS (2005)
Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination
E Warner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition
M Kriege et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment
ME Robson et al.
BREAST CANCER RESEARCH (2004)
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history:: A combined analysis of 22 studies
A Antoniou et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
BRCA2 germline mutations in familial pancreatic carcinoma
SA Hahn et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
A significant response to neoadjuvant chemotherapy in BRCA1/2 related breast cancer
PO Chapppuis et al.
JOURNAL OF MEDICAL GENETICS (2002)
Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer
JMJ Piek et al.
JOURNAL OF PATHOLOGY (2001)
Occult carcinoma in prophylactic oophorectomy specimens - Prevalence and association with BRCA germline mutation status
TJ Colgan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2001)
Breast MR imaging screening in 192 women proved or suspected to be carriers of a breast cancer susceptibility gene: Preliminary results
CK Kuhl et al.
RADIOLOGY (2000)
Share Paper
